Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie som sammenligner Siplizumab med kanin anti-thymocytglobulin for å hjelpe kroppen med å akseptere en nyretransplantasjon (MODERNIZE1)

6. november 2026 oppdatert av: ITB-Med LLC

Fase 2b, randomisert, multikenter, dobbeltblind, doseringsfinner, aktivkontrollert studie av Siplizumab (TCD601) sammenlignet med kanin anti-thymocytglobulin hos nyretransplantasjonsmottakere som krever induksjonsterapi og mottar standardbehandling med immunsuppresjon med Tacrolimus, mykofenolsyre og kortikosteroider

The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:

How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?

How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.

How does the body respond to siplizumab after dosing at each of the 2 dose levels?

How does siplizumab work in the body compared to rATG?

Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.

Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.

Participants will be monitored for 12 months after transplant surgery.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.

Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:

  • A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
  • Premedication prior to study treatment infusions.
  • Infection prophylaxis

This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.

Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.

Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.

Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.

Studietype

Intervensjonell

Registrering (Antatt)

120

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brasil, 30150-320
        • Rekruttering
        • Santa Casa Demisericordia de Belo Horizonte
        • Ta kontakt med:
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasil, 90035-903
        • Rekruttering
        • Hospital de Clinicas de Porto Alegre
        • Ta kontakt med:
      • Porto Alegre, Rio Grande do Sul, Brasil, 90020-090
        • Rekruttering
        • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
        • Ta kontakt med:
    • São Paulo
      • São José do Rio Preto, São Paulo, Brasil, 15090-000
        • Rekruttering
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
        • Ta kontakt med:
      • São Paulo, São Paulo, Brasil, 04038-002
        • Rekruttering
        • Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
        • Ta kontakt med:
    • California
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • Keck Hospital of the University of Southern California
        • Ta kontakt med:
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • University of California - Los Angeles, Connie Frank Kidney Transplant Center
        • Ta kontakt med:
      • Sacramento, California, Forente stater, 95817
        • Rekruttering
        • UC Davis Medical Center
        • Ta kontakt med:
    • Florida
      • Tampa, Florida, Forente stater, 33606
        • Rekruttering
        • Tampa General Hospital
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Rekruttering
        • Emory University Hospital
        • Ta kontakt med:
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • Rekruttering
        • University of Kansas Hospital
        • Ta kontakt med:
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40536
        • Rekruttering
        • University of Kentucky Healthcare
        • Ta kontakt med:
    • Louisiana
      • Metairie, Louisiana, Forente stater, 70006
        • Rekruttering
        • Tulane Medical Center
        • Ta kontakt med:
    • Massachusetts
      • Worcester, Massachusetts, Forente stater, 01655
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Rekruttering
        • University of Michigan - Michigan Medicine
        • Ta kontakt med:
          • Nerissa Reister, Clinical Research Coordinator
          • Telefonnummer: 734-763-5718
          • E-post: naflow@med.umich.edu
      • Detroit, Michigan, Forente stater, 48202
        • Rekruttering
        • Henry Ford Health
        • Ta kontakt med:
    • New Jersey
      • Livingston, New Jersey, Forente stater, 07039
        • Rekruttering
        • Cooperman Barnabus Medical Center
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10032
        • Rekruttering
        • New York Presbyterian - Columbia University Irving Medical School
        • Hovedetterforsker:
          • Lloyd Ratner, MD
        • Ta kontakt med:
        • Ta kontakt med:
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • New York Presbyterian - Weill Cornell Medical Center
        • Ta kontakt med:
        • Ta kontakt med:
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University Medical Center
        • Ta kontakt med:
    • Texas
      • Dallas, Texas, Forente stater, 75390
    • Virginia
      • Falls Church, Virginia, Forente stater, 22042
        • Rekruttering
        • Inova Fairfax Hospital
        • Ta kontakt med:
      • Richmond, Virginia, Forente stater, 23298
        • Rekruttering
        • Virginia Commonwealth University Health
        • Ta kontakt med:
    • Washington
      • Seattle, Washington, Forente stater, 98195
        • Rekruttering
        • University of Washington Medical Center
        • Ta kontakt med:
          • Belinda Pan, Research Coordinator
          • Telefonnummer: 206-598-1562
          • E-post: bcpan@uw.edu
      • Barcelona, Spania, 08035
        • Rekruttering
        • Hospital Universitari Vall D'Hebron
        • Ta kontakt med:
      • Córdoba, Spania, 14004
      • Málaga, Spania, 29010
        • Rekruttering
        • Hospital Universitario Regional de Malaga
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 70 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Recipients of a renal allograft from a non-HLA identical living or deceased donor.
  • Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.

Exclusion Criteria:

  • Transplant recipients seronegative for EBV.
  • Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
  • Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
  • Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
  • Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
  • ABO-incompatible recipient.
  • Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
  • Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
  • History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
  • Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
  • Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
  • Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
  • Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Lav dose siplizumab

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Andre navn:
  • TCD601
Eksperimentell: Høy dose siplizumab

A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

Andre navn:
  • TCD601
Aktiv komparator: Kanin anti-thymocytt globulin

An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits

Andre navn:
  • Thymoglobulin

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Tidsramme: 12 months

Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs).

12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
  • Composite incidence of BPAR, death, graft loss, and loss-to-follow-up.
  • Incidence of participants who experienced BPAR as defined by central pathology (blinded independent central review using Banff Allograft Pathology Scoring).
  • Incidence of treated BPAR and steroid-resistant BPAR.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months

• Grade of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months

• Severity of BPAR.

12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
  • Time to first BPAR for each participant.
  • Time to graft loss for each participant.
  • Time to death for each participant.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months
  • Participant survival at 12 months.
  • Graft survival at 12 months.
12 months
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Tidsramme: 12 months

• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant.

12 months
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Tidsramme: 12 weeks

Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Tidsramme: 12 weeks

Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant.

12 weeks
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Tidsramme: 12 months

Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant.

12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. juni 2026

Primær fullføring (Antatt)

28. mars 2028

Studiet fullført (Antatt)

28. mars 2028

Datoer for studieregistrering

Først innsendt

11. mars 2026

Først innsendt som oppfylte QC-kriteriene

27. mars 2026

Først lagt ut (Faktiske)

2. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • TCD601B205

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .